GnuBio Bio-Rad Shutters Former GnuBio Facility as Part of Digital Biology R&D Consolidation The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments. Bio-Rad Q3 Revenues Jump 6 Percent NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market on Tuesday a 5 percent increase in third quarter revenues including a 6 percent spike in sales for its Life Science segment. Bio-Rad Aims to Launch GnuBio Sequencer within Two Years, Discloses Purchase Price of up to $110M Premium This article was originally published May 12. Life Science Sales Boost Bio-Rad Q1 Revenues; Firm Details Droplet-based Sequencing Tech Investment Premium NEW YORK (GenomeWeb) — Bio-Rad this week reported a net sales increase of 3 percent in its Life Science segment in the first quarter versus the same period last year. Bio-Rad Q1 Revenues Up 2 Percent; Will Pay Up to $110M for GnuBio NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues increased 2 percent as its Life Science sales spiked 3 percent year over year. Apr 15, 2014 Bio-Rad Buys GnuBio; Will Focus on NGS-based Dx for Oncology, HLA, Infectious Disease Premium Apr 11, 2014 Bio-Rad Acquires Sequencing Technology Developer GnuBio Oct 1, 2013 GnuBio Unveils Sequencer at Consumer Genetics Conference, Reports Zero Error Rate in Internal Tests Premium Jun 6, 2013 UCSF, QB3 Team Pairs Picoinjection with Droplet-based PCR; Founds Single-Cell PCR Firm Torrent Bio Premium Feb 19, 2013 New Products: Personalis' Sequencing and Interpretation Services; GnuBio to Ship Beta System Premium Oct 23, 2012 Paired Ends: Susie Truong Harborth Premium Oct 4, 2012 GnuBio Raises $10M in Private Financing Sep 14, 2012 NHGRI Injects $19M into Projects to Fuel Faster Sequencing Sep 11, 2012 GnuBio Maxes out New Office Space as it Preps for Commercial Launch Premium Sep 6, 2012 GnuBio Moves to Bigger Space as it Prepares to Launch Desktop Sequencing Platform Apr 24, 2012 With Illumina Acquisition on Ice, What is Roche's Next Move in the Sequencing Space? Premium Feb 28, 2012 Targeting Launch of Platform by Year's End, GnuBio Bets on Gene Panels, Replacing Sanger Assays Premium Feb 1, 2012 Montreal Heart Institute Developing GnuBio Sequencing Panel for Sudden Cardiac Death Test Premium Jan 11, 2012 Montreal Heart Institute Developing Cardiac Screening Panel for GnuBio Sequencer Jan 3, 2012 Desktop Sequencers Take Center Stage in 2011 as Platform Providers Face Tough Times Premium Dec 16, 2011 In Brief This Week: Danaher; Sequenom; Complete Genomics; PerkinElmer; GnuBio; Novozymes, Morphosys; OGI Dec 13, 2011 Aiming for Q2 2012 Launch, GnuBio Builds Beta Version of Microfluidics-Based Sequencing System Premium Oct 4, 2011 GnuBio Targets 1K-Base Reads for Commercial Launch of $50K Sequencer Premium Sep 7, 2011 GnuBio Completes Series A Equity Round Raising $8M Jul 19, 2011 GnuBio Starts Early-Access Testing of Instrument at Montreal Heart Institute Premium Load More Breaking News Genetic Contributors to Plasma Protein Levels Unearthed in Multiple Studies Standard BioTools, SomaLogic to Merge Arima Genomics, Protean BioDiagnostics Launch 3D Genomics Cancer Testing Joint Venture Pathnostics UTI Test Nabs New York State Approval NanoString, A*Star, Next Level Genomics to Launch Spatial Biology Laboratory in Singapore The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.